Toyota|$17.53 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$21.28 (¥3,433)+1.30%▲ (in JPY terms)
SoftBank|$36.74 (¥5,928)-6.79%▼ (in JPY terms)
MUFG|$22.54 (¥3,636)-1.65%▼ (in JPY terms)
Keyence|$460.03 (¥74,220)-3.13%▼ (in JPY terms)
Nintendo|$43.80 (¥7,066)+0.74%▲ (in JPY terms)
NTT|$0.94 (¥151)+0.93%▲ (in JPY terms)
Takeda|$33.36 (¥5,382)+1.78%▲ (in JPY terms)
Tokyo Electron|$430.71 (¥69,490)-6.40%▼ (in JPY terms)
Recruit|$78.75 (¥12,705)+0.99%▲ (in JPY terms)
ITOCHU|$11.90 (¥1,920)-0.83%▼ (in JPY terms)
Honda|$9.66 (¥1,559)+3.14%▲ (in JPY terms)
Shin-Etsu|$45.22 (¥7,296)-5.12%▼ (in JPY terms)
Tokio Marine|$47.54 (¥7,670)-1.31%▼ (in JPY terms)
Fast Retailing|$486.56 (¥78,500)-0.42%▼ (in JPY terms)
Toyota|$17.53 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$21.28 (¥3,433)+1.30%▲ (in JPY terms)
SoftBank|$36.74 (¥5,928)-6.79%▼ (in JPY terms)
MUFG|$22.54 (¥3,636)-1.65%▼ (in JPY terms)
Keyence|$460.03 (¥74,220)-3.13%▼ (in JPY terms)
Nintendo|$43.80 (¥7,066)+0.74%▲ (in JPY terms)
NTT|$0.94 (¥151)+0.93%▲ (in JPY terms)
Takeda|$33.36 (¥5,382)+1.78%▲ (in JPY terms)
Tokyo Electron|$430.71 (¥69,490)-6.40%▼ (in JPY terms)
Recruit|$78.75 (¥12,705)+0.99%▲ (in JPY terms)
ITOCHU|$11.90 (¥1,920)-0.83%▼ (in JPY terms)
Honda|$9.66 (¥1,559)+3.14%▲ (in JPY terms)
Shin-Etsu|$45.22 (¥7,296)-5.12%▼ (in JPY terms)
Tokio Marine|$47.54 (¥7,670)-1.31%▼ (in JPY terms)
Fast Retailing|$486.56 (¥78,500)-0.42%▼ (in JPY terms)

2026-07-13 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received approval in the United States as neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer, regardless of whether cisplatin is indicated, in combination with pembrolizumab.”

by

2026-07-13 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received approval in the United States as neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer, regardless of whether cisplatin is indicated, in combination with pembrolizumab.”

Tags: Astellas Pharma Inc.JP3942400007

コメントする

Contact